Tampa, Florida-based biotechnology company developing a proprietary pipeline of neuroplastogens and non-hallucinogenic derivatives of psychedelics such as DMT for CNS disorders including mood, cognitive and substance use disorders. Its lead candidate is PSIL-006, a non-hallucinogenic compound targeting neurological disorders including frontotemporal dementia. In early 2025 it licensed its DMT intellectual property to AtaiBeckley.
Psilera News 10 articles
- Psilera Receives Positive Preclinical in Vivo Data for Frontotemporal Dementia (FTD) Candidate, PSIL-006
- Psilera Welcomes Biopharma Executive Dr. Magali Haas to its Board of Directors
- Psilera Unveils Novel, Non-Hallucinogenic Psilocybin Derivative PSIL-006 As Lead Clinical Candidate
- Psilera to Sponsor and Present at Wonderland: Miami (November 3-5 2022)
- Psilera Receives First Patent Allowance for Transdermal Patch Formulations
- Psilera’s New Compounds Show Potential for Significant Treatment Improvement in Depression and Neurodegenerative Disorders
- Dr. Chris Witowski, CEO of Psilera Bioscience, Sits in the Investor Hotseat: Stream #2
- Jackie von Salm: On Raising $2.5 million at Psilera to Further Cutting Edge Psychedelic Research
- Psilera Bioscience: Developing the Next Generation of Safer, Targeted Psychedelic Therapies
- USF Connect’s Tampa Bay Technology Incubator Propels Homegrown Researchers at Biotech Startup Psilera Bioscience